SI-BONE reports Q3 revenue $40.3M (+19% YoY); expects positive Adjusted EBITDA in Q4

SI-BONE, Inc.

2024-Q3 EPS reported -$0.64 revenue$118,176,000

Worldwide revenue $40.3M (+19% YoY); U.S. revenue $38.3M (+18% YoY).
Net loss improved 34% to $6.6M; Adjusted EBITDA loss narrowed 94% to $0.2M.
Over 1,200 active U.S. physicians (+15%); commercialized iFuse TORQ TNT for pelvic fractures.
Updated FY2024 revenue guidance to $165-166M (prev $165-167M); expects Adj EBITDA positive in Q4.
Refinanced $36M term loan, lowered borrowing cost, extended maturity to 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.